Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T A Dunn

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Risk Management (New York, N.Y.)|November 8, 1978
Self insurance: treatment for the hospital malpractice coverage crisisT A Dunn
Educational Directions for Dental Auxiliaries|September 1, 1977
Individualizing dental hygiene instructionT A Dunn
Tissue Antigens|November 13, 2001
Identification of a novel DR4 allele, DRB1*0442T A Dunn, B A Iglehart, M S Leffell
Investigational New Drugs|January 1, 1997
Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenograftsT A Dunn, V Grünwald, C Bokemeyer, et al.
Anti-Cancer Drugs|September 1, 1996
Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancerT A Dunn, H J Schmoll, V Grünwald, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 1998
Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell linesT A Dunn, H J Schmoll, C Rie, et al.
Investigational New Drugs|January 1, 1997
Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell linesT A Dunn, H J Schmoll, V Grünwald, et al.
The Medical Journal of Australia|April 5, 1993
Chloroquine-resistant Plasmodium vivax: how common?J M Robson, D Conroy, J M Cremin, et al.
Anticancer Research|July 1, 1993
Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788T Efferth, T A Dunn, M Berlion, et al.
Oncogene|May 6, 1998
The EWS/ATF1 fusion protein contains a dispersed activation domain that functions directlyS Pan, K Y Ming, T A Dunn, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Risk Management (New York, N.Y.)|November 8, 1978
Self insurance: treatment for the hospital malpractice coverage crisisT A Dunn
Educational Directions for Dental Auxiliaries|September 1, 1977
Individualizing dental hygiene instructionT A Dunn
Tissue Antigens|November 13, 2001
Identification of a novel DR4 allele, DRB1*0442T A Dunn, B A Iglehart, M S Leffell
Investigational New Drugs|January 1, 1997
Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenograftsT A Dunn, V Grünwald, C Bokemeyer, et al.
Anti-Cancer Drugs|September 1, 1996
Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancerT A Dunn, H J Schmoll, V Grünwald, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 1998
Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell linesT A Dunn, H J Schmoll, C Rie, et al.
Investigational New Drugs|January 1, 1997
Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell linesT A Dunn, H J Schmoll, V Grünwald, et al.
The Medical Journal of Australia|April 5, 1993
Chloroquine-resistant Plasmodium vivax: how common?J M Robson, D Conroy, J M Cremin, et al.
Anticancer Research|July 1, 1993
Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788T Efferth, T A Dunn, M Berlion, et al.
Oncogene|May 6, 1998
The EWS/ATF1 fusion protein contains a dispersed activation domain that functions directlyS Pan, K Y Ming, T A Dunn, et al.
Pageof 2